Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC

Oncogene

Volumn 35, Issue 33, 2016, Pages 4345-4357

  Taylor, M A ^a   Wappett, M ^a   Delpuech, O ^a   Brown, H ^a   Chresta, C M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 29B; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TET1 ENZYME; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG; 5 METHYLCYTOSINE; 5-HYDROXYMETHYLCYTOSINE; AZACITIDINE; ETS1 PROTEIN, HUMAN; MICRORNA; MIRN29 MICRORNA, HUMAN; MIXED FUNCTION OXIDASE; ONCOPROTEIN; TET1 PROTEIN, HUMAN;

ARTICLE; ATAXIA TELANGIECTASIA; EPIGENETIC REPRESSION; GENE EXPRESSION PROFILING; IMMUNE EVASION; LUNG CANCER CELL LINE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; ANALOGS AND DERIVATIVES; BIOLOGY; DOWN REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; LUNG TUMOR; MAPK SIGNALING; METABOLISM; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR ESCAPE;

5-METHYLCYTOSINE; AZACITIDINE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DOWN-REGULATION; EPIGENESIS, GENETIC; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICRORNAS; MIXED FUNCTION OXYGENASES; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEINS; TUMOR ESCAPE;

EID: 84954483998     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.499     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Nana-Sinkam SP, Powell CA. Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5 Suppl): e30S-e309.
3. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
5. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006; 24: 5079-5090.
6. Taylor MA, Schiemann WP. Therapeutic opportunities for targeting microRNAs in cancer. Mol Cell Ther [Review] 2014; 2: 1-13.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
8. Liu A, Tetzlaff MT, Vanbelle P, Elder D, Feldman M, Tobias JW et al. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol 2009; 2: 519-527.
9. Devarajan K. Nonnegative matrix factorization: an analytical and interpretive tool in computational biology. PLoS Comput Biol 2008; 4: e1000029.
10. Senbabaoglu Y, Michailidis G, Li JZ. Critical limitations of consensus clustering in class discovery. Sci Rep 2014; 4: 6207.
11. Lee ES, Son DS, Kim SH, Lee J, Jo J, Han J et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008; 14: 7397-7404.
12. The Cancer Genome Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
13. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 2010; 16: 4864-4875.
14. Del Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, Mantovani A. Molecular pathways in cancer-related inflammation. Biochem Med (Zagreb) 2011; 21: 264-275.
15. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
16. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3: 1355-1363.
17. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014; 25: 1935-1940.
18. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015; 112: 95-102.
19. Ramirez-Valle F, Braunstein S, Zavadil J, Formenti SC, Schneider RJ. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol 2008; 181: 293-307.
20. Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol Ther 2014; 149: 124-138.
21. Wojtalla A, Fischer B, Kotelevets N, Mauri FA, Sobek J, Rehrauer H et al. Targeting the phosphoinositide 3-kinase p110-alpha isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer. Clin Cancer Res 2013; 19: 96-105.
22. Dhillon T, Mauri FA, Bellezza G, Cagini L, Barbareschi M, North BV et al. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol 2010; 5: 314-319.
23. Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 2009; 15: 1277-1287.
24. Liu S, Liang Y, Huang H, Wang L, Li Y, Li J et al. ERK-dependent signaling pathway and transcriptional factor Ets-1 regulate matrix metalloproteinase-9 production in transforming growth factor-beta1 stimulated glomerular podocytes. Cell Physiol Biochem 2005; 16: 207-216.
25. Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD et al. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 2010; 31: 577-586.
26. Lan MS, Breslin MB. Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation. FASEB J 2009; 23: 2024-2033.
27. Ficz G, Gribben JG. Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence? Genomics 2014; 104: 352-357.
28. Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 2011; 42: 451-464.
29. Jin C, Lu Y, Jelinek J, Liang S, Estecio MR, Barton MC et al. TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells. Nucleic Acids Res 2014; 42: 6956-6971.
30. Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber J et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011; 473: 343-348.
31. Wu BK, Brenner C. Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation. Cell Rep 2014; 9: 1827-1840.
32. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367-1380.
33. Liao RG, Watanabe H, Meyerson M, Hammerman PS. Targeted therapy for squamous cell lung cancer. Lung Cancer Manag 2012; 1: 293-300.
34. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150: 12-27.
35. Huang Y, Rao A. Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet 2014; 30: 464-474.
36. Jacobsen A, Silber J, Harinath G, Huse JT, Schultz N, Sander C. Analysis of microRNA-target interactions across diverse cancer types. Nat Struct Mol Biol 2013; 20: 1325-1332.
37. Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH et al. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res 2014; 42(Database issue): D78-D85.
38. Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I et al. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res 2015; 43(Database issue): D153-D159.
39. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805-15810.
40. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011; 226: 2378-2390.
41. Lin YC, Shih JY, Huang WJ, Chao SW, Chang YL, Chen CC. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers. Clin Cancer Res 2015; 21: 428-438.
42. Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ et al. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells. Oncol Rep 2013; 29: 1975-1982.
43. Lou YF, Zou ZZ, Chen PJ, Huang GB, Li B, Zheng DQ et al. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PLoS One 2014; 9: e97719.
44. Sajadian SO, Ehnert S, Vakilian H, Koutsouraki E, Damm G, Seehofer D et al. Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent and suggests new treatment strategies against hepatocellular carcinoma. Clin Epigenet 2015; 7: 98.
45. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics 2010; 11: 367.
46. Lopez-Romero P. Pre-processing and differential expression analysis of Agilent microRNA arrays using the AgiMicroRna Bioconductor library. BMC Genomics 2011; 12: 64.
47. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
48. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011; 27: 1739-1740.
49. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-1061.